WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Shooting injures 2 at Missouri high school graduation ceremony
Donald Trump trial LIVE: Michael Cohen says ex
Report urges fixes to online child exploitation CyberTipline before AI makes it worse
Biden administration tightens rules for obtaining medical records related to abortion
Independent UN experts urge Yemen’s Houthis to free detained Baha'i followers
European nations with Patriot missiles hesitate to give the air defense systems to Ukraine
Serie A title, second star and derby: Inter takes it all with win over Milan
Met officer admits dispersal order 'breached by Tommy Robinson at march against anti
Rangers are undefeated at .500 to keep World Series champs from a losing record with Bochy
Cleveland to pay $4.8M to family of teen killed by stolen car during police chase
Everybody may love Raymond, but Ray Romano loves Peter Boyle
Met officer admits dispersal order 'breached by Tommy Robinson at march against anti